EarliTec Diagnostics

EarliTec Diagnostics specializes in developing tools and devices for the detection of Autism Spectrum Disorder (ASD) and related disabilities. Its proprietary diagnostic tool measures a child’s preferential attention to social information based on their eye movement, supporting early detection of ASD. A child is shown a series of short videos showing social interaction, while the firm's eye-tracking technology monitors focus and responsiveness. This data is then compared to age-expected reference metrics to determine potential developmental conditions.

In June 2022, the company received FDA 510(k) approval for ‘EarliPoint Evaluation’, a device used for the diagnosis and assessment of ASD among children between the ages of 16 and 30 months. The technology behind EarliPoint quantifies social-visual engagement, providing clinicians with an objective, quick, and precise reading of autism presence, degree of social disability, and verbal and non-verbal learning levels. The firm plans to continue clinical research and expand partnerships within the ASD community.

Key customers and partnerships

As of April 2024, 12 EarliPoint devices were in use across eight centers in six US states.